Issue of shares pursuant to incentive scheme
Source: RNS
Syncona Limited
Issue of shares pursuant to incentive scheme and PDMR dealings
15 July 2022
Syncona Ltd (the "Company"), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today announces that a total of 2,595,736 new ordinary shares (representing 0.39% of the Company's existing issued ordinary shares) will be issued in satisfaction of realisations under the Company's long term incentive scheme. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the incentive scheme, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 13 July 2022, £1.964.
In accordance with the rules of the incentive scheme, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.
The issue of shares include the following shares to be issued to senior members of the Syncona Investment Management Limited (SIML) leadership team:
|
Name |
SIML Title |
No. of shares to be issued |
|
Martin Murphy |
Chief Executive Officer |
993,527 |
|
Chris Hollowood |
Chief Investment Officer |
642,815 |
Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 20 July 2022.
Following admission, the Company will have 669,329,324 ordinary shares in issue and the total number of voting rights in the Company will be 669,329,324. The Company does not hold any ordinary shares in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interests in, the Company under the FCA's Disclosure and Transparency Rules.
Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.
[ENDS]
Enquiries
Syncona Ltd
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 7714 916615
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses, across development stage and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
|
1. |
Details of PDMR / person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Martin Murphy |
||||
|
b) |
Position / status |
Chief Executive Officer, SIML |
||||
|
c) |
Initial notification / amendment |
Initial Notification |
||||
|
2. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares GG00B8P59C08 |
||||
|
b) |
Nature of the transaction |
Issue of shares pursuant to the Syncona long term incentive scheme |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A |
||||
|
e) |
Date of the transaction |
14 July 2022 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
|
g) |
Currency |
GBP - British Pound |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Chris Hollowood |
||||
|
b) |
Position / status |
Chief Investment Officer, SIML |
||||
|
c) |
Initial notification / amendment |
Initial Notification |
||||
|
2. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares GG00B8P59C08 |
||||
|
b) |
Nature of the transaction |
Issue of shares pursuant to the Syncona long term incentive scheme |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A |
||||
|
e) |
Date of the transaction |
14 July 2022 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
|
g) |
Currency |
GBP - British Pound |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
